Latest News
HighTide Therapeutics and Quotient Sciences have signed an agreement to support HighTide’s HTD1801 program.
Details
Molecule to cure. Fast.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Because humanity needs solutions, fast.
Watch our video
Welcome to Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
Our services
At Quotient Sciences, we’ve streamlined the drug development process by providing pre-formulation screening, formulation development, first-in-human trials, and clinical & commercial manufacturing services all at one CDMO & CRO. This allows us to support drug development programs from candidate selection through to commercial supply.
Latest updates
-
NewsHighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company focusing on novel multifunctional therapeutics for metabolic and digestive diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have signed an agreement to support HighTide’s HTD1801 program.
-
Jan 9EventBiotech Showcase 2023Schedule a 1:1 partnering meeting with our integrated drug development experts at Biotech Showcase 2023 in San Francisco, January 9-11.
-
Info SheetQuotient Sciences' Collaboration with Charles RiverIntegrated programs that bridge molecules from early discovery to proof of concept (POC) and beyond.
-
WebinarNavigating the Small Molecule CMC PathwayLearn about drug substance and formulation considerations for improving downstream clinical outcomes. Access on demand.
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.